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Abstract
Background: Lung cancer has long been the most dangerous malignant tumor among males in both well
developed and poorly developed countries. Radiotherapy plays a critical role in the curative management of
inoperable non-small cell lung cancer (NSCLC) and is also used as a post-surgical treatment in lung cancer patients.
Radioresistance is an important factor that limits the efficacy of radiotherapy for NSCLC patients. Increasing
evidence suggests that microRNAs (miRNAs) possess diverse cellular regulatory roles in radiation responses.
Methods: In this study, we used miRNA microarray technology to identify serum miRNAs that were differentially
expressed before and after radiotherapy in lung cancer patients. We further examined the biological function of
miR-208a on cell viability, apoptotic death and cell cycle distribution in human lung cancer cells and explored the
probable mechanism.
Results: Nine miRNAs, including miR-29b-3p, miR-200a-3p, and miR-126-3p were significantly down-regulated,
whereas miR-208a was the only miRNA that was up-regulated in the serum of the patients after radiation treatment
(P < 0.05). The expression of miR-208a could be induced by X-ray irradiation in lung cancer cells. Forced expression
of miR-208a promoted cell proliferation and induced radioresistance via targeting p21 with a corresponding
activation of the AKT/mTOR pathway in lung cancer cells, whereas down-regulation of miR-208a resulted in the
opposite effects. In addition, down-regulation of miR-208a increased the percentage of cells undergoing apoptosis
and inhibited the G1 phase arrest in NSCLC cells. Moreover, miR-208a from the serum exosome fraction of lung
cancer patients could shuttle to A549 cells in a time-dependent manner, which was likely to contribute to the
subsequent biological effects.
Conclusions: The present study provides evidence that miR-208a can affect the proliferation and radiosensitivity of
human lung cancer cells by targeting p21 and can be transported by exosomes. Thus, miR-208a may serve as a
potential therapeutic target for lung cancer patients.
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Background
Lung cancer has long been the most dangerous malig-
nant tumor among males in both well developed and
poorly developed countries and has surpassed breast
cancer as the leading cause of cancer death among fe-
males in well developed countries [1]. Non-small cell
lung cancer (NSCLC) and small cell lung cancer (SCLC)
are the main types of lung cancer according to morpho-
logic type, with NSCLC accounting for ~80–85 % of the
tumors diagnosed in all lung cancer patients [2]. Radio-
therapy plays a critical role in the curative management
for inoperable NSCLC and shows promise as a post-
surgical treatment for lung cancer patients [3]. One en-
couraging report suggested that stereotactic ablative
radiotherapy (SABR) was a valuable adjunctive treatment
for operable stage I NSCLC and that SABR might lead
to better overall survival than surgery alone for operable
clinical stage I NSCLC [4].
Radioresistance is an important factor that limits the
efficacy of radiotherapy for NSCLC patients. Resistance
to radiotherapy can be attributed either to intrinsic
radioresistance of the tumor cells within the hypoxia
microenvironment or to resistance acquired during frac-
tionated radiotherapy [5, 6]. One of the molecular events
by which tumors become radioresistant is radiation-
induced activation of signal transduction pathways, such
as those regulated by membrane-bound receptor tyro-
sine kinases (RTKs) [5]. Hypoxia-inducible factor 1α
(HIF-1α) and reactive oxygen species (ROS) have been
reported to mediate radiation-induced invasiveness in
lung carcinoma cells [7]. However, the key molecules in-
volved in radiation-induced radioresistance remain
poorly understood. Thus, knowledge of the functional
mechanisms is urgently warranted to overcome radiore-
sistance during cancer therapy.
MicroRNAs (miRNAs) are small non-coding RNAs
that specifically regulate gene expression by directly
cleaving the targeted mRNAs or inhibiting translation by
interacting with the 3′ untranslated regions (UTRs) of
the mRNA targets to increase or inhibit their translation
[8]. Increasing evidence suggests that miRNAs possess
diverse cellular regulatory roles, and some miRNAs have
been shown to function as either oncogenes or tumor
suppressors [9]. Reduced let-7 expression was signifi-
cantly associated with reduced postoperative survival
[10], while the miR-17-92 cluster was reported to act as
oncogenes that enhanced lung cancer cell growth [11].
Upon irradiation, multiple miRNAs are altered during
the shift in the balance between radioresistance and cell
death [12, 13]. For example, up-regulation of let-7, miR-
210 and miR-21 induces the resistance of lung cancer
cells to radiotherapy [14–16]. However, all these studies
focused on a specific set of miRNAs in vitro and did not
address their clinical significance.
Cells may communicate by chemical receptor-mediated
events, direct cell-to-cell contact and cell-to-cell synapses
[17–19]. However, attention is now being focused on cell-
to-cell communication that involves spherical membrane
fragments called microvesicles [20]. Exosomes are one of
these membrane-derived vesicles released by many cells.
They have recently been recognized as important media-
tors of intercellular communication, on the basis that they
carry lipids, proteins, mRNAs and various microRNAs
including let-7, miR-1, miR-15, miR-16, miR-181 and
miR-375, which can be transferred to a recipient cell via
fusion of the exosome with the target cell membrane [21].
Exosomes may play an important role in transporting
radiation-induced serum miRNAs and subsequently affect
the proliferation and radioresistance of human lung
cancer cells.
Thus, the purpose of this study was to identify the key
serum miRNAs associated with radioresistance in
NSCLC. We first investigated the changes in the expres-
sion profile of the miRNAs in the serum of lung cancer
patients who had been treated with radiotherapy. We then
studied the role of the apparently up-regulated miRNA in
the proliferation and radioresistance of NSCLC and evalu-
ated the probable mechanism. Our findings also provide a
possible explanation of the mechanisms by which NSCLC
cells could acquire and regulate resistance to radiation
through components of the serum.
Methods
Patients and serum samples
For miRNA microarray and quantitative real-time
polymerase chain reaction (qRT-PCR) analyses, serum
samples of lung cancer patients were obtained from
Changzhou Cancer Hospital (Changzhou, China) be-
tween June 2012 and March 2014. Venous blood was
drawn from 60 volunteers before radiotherapy (BR)
and only half of the compliant serums were obtained
24 h after receiving 60 Gy radiotherapy (AR). All of
the collected blood samples were held at room
temperature for 60 min. After centrifugation at 3000 ×
g for 10 min, the supernatants were collected and im-
mediately frozen at −80 °C to preserve them until fur-
ther use. The patients in this study had not been
subjected to chemotherapy, and their tumors were
diagnosed as carcinomas on the basis of pathological
evidence: the histological features of the specimens
were evaluated by two senior pathologists. All patients
gave signed, informed consent for their blood to be
used for scientific research. Ethical approval for this
study was obtained from Changzhou Cancer Hospital
Affiliated to Soochow University. All experiments were
performed in accordance with the relevant guidelines
and regulations of Soochow University.
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Serum miRNA microarray
The miRNA microarray experiments were performed to
identify the differentially expressed miRNAs. Total
RNAs were extracted from the paired serum samples
(before and after radiotherapy) from three patients with
an age range of 54 to 66 years. All samples passed the
quality control analysis, and no signs of PCR reaction in-
hibition were observed. A microRNA PCR panel (V3.M;
Exiqon, Vedbaek, Denmark) was used to evaluate the
miRNA profiles in this study. The RNAs were labeled
and hybridized following the manufacturer’s instructions
at KangChen Bio-tech (Shanghai, China).
qRT-PCR validation of miRNA expression
qRT-PCR analysis was performed to evaluate the miR-
208a expression in this study. The specific stem-looped
qRT-PCR primers for miR-208a, miR-29b-3p, miR-126-
3p and miR-200a-3p were designed by GenePharma Co.
Ltd. (Shanghai, China). The qRT-PCR analysis was per-
formed on an ABI 7500 instrument (Applied Biosystems,
Foster City, CA, USA) using TaqMan-based microRNA
assays according to the manufacturer’s protocols as de-
scribed in our previous study [22]. U6 and miR-16 were
measured by the same method and used to normalize
the cell samples and serum samples, respectively. The
relative quantity of each miRNA in the serum or cells,
normalized to U6 or miR-16 and relative to the expression
of those samples before radiotherapy, was calculated using
the equation RQ = 2-ΔΔCT, where ΔΔCT = (CTmiRNA -
CTU6 or miR-16) AR - (CTmiRNA - CT U6 or miR-16) BR, and
the CT value was the threshold cycle for the detection of
fluorescence. After amplification, melting curve analysis
was performed to ensure the specificity of the products.
For cellular medium miRNA analysis, we first col-
lected the medium incubated with A549 cells after 0 or
4 Gy X-ray irradiation. The supernatants were centri-
fuged at 7,500 × g for 40 min using an ultra-filtration
membrane tube (10 kDa, Merck Millipore, Darmstadt,
Germany). The concentrated solution was then har-
vested using TRIzol reagent (Tiangen, Beijing, China)
and further for qRT-PCR analysis.
Cell cultures and irradiation
The human NSCLC cell lines (A549, H1299, H1975 and
H460) and human non-cancerous bronchial epithelial
cell lines (BEAS-2B and HBE) were maintained in
Dulbecco’s Modified Eagles Medium (DMEM) supple-
mented with 10 % fetal bovine serum (FBS) (Gibco,
Grand Island, NY, USA) at 37 °C in 5 % CO2. The lung
cancer patients received a total dose of 60 Gy X-ray from
a linear accelerator (Varian, Palo Alto, CA, USA) at a dose
rate of 2 Gy/min. The cells were exposed to a single dose
of X-rays using a linear accelerator (RadSource, Suwanee,
GA, USA) at a dose rate of 1.15 Gy/min and 160 kv X-ray
energy.
RNA synthesis and cellular transfection
The miR-208a mimics and negative control miRNA
(miRNA-NC) or miR-208a inhibitor and inhibitor-NC
were all synthesized by GenePharma Co. Ltd. (Shanghai,
China). The synthetic RNAs were transfected into cells
using Lipofect reagent (Tiangen, Beijing, China) accord-
ing to the manufacturer’s instructions.
Luciferase assays
A luciferase reporter that contained the full-length 3′
UTR of p21 (pGL3-UTR-WT) and the mutant reporter
plasmid with mutation of the miR-208a binding site
(pGL3-UTR-MUT) were constructed by Synbio Tech,
Ltd. (Suzhou, China). For luciferase assay, 500 ng of the
reporter vector was cotranfected with 500 ng synthetic
RNA in a 24-well plate. 30 ng of pRL-TK (Promega,
Madison, WI) was also transfected to correct the transfec-
tion efficiency. The luciferase activity was measured with
the Dual-Luciferase Reporter Assay System (Promega).
The ratio of Firefly luciferase to Renilla luciferase activities
were considered as promoter activities.
Cell proliferation assay
The cells were seeded in a 96-well plate at a density of
2 × 103 cells per well. The cells were transfected with 50
nM of either miR-208a mimics and miRNA-NC or miR-
208a inhibitor and inhibitor-NC 24 h later and allowed
to grow for another 48 h. The cell proliferation was
measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl-2Htetrazolium bromide (MTT) assay 48 h after
the transfection with the RNAs. Briefly, 20 μL of the
MTT solution (5 mg/mL) was added to each well, and
the cells were incubated for another 4 h at 37 °C. The
medium was then aspirated, and 150 μL of dimethylsulf-
oxide (DMSO) was added to dissolve the crystals. The
optical density was measured at 492 nm using a micro-
plate reader (Bio-Rad, Hercules, CA, USA). The viability
index was calculated as the experimental OD value/the
control OD value. Three independent experiments were
performed in quadruplicate.
5-ethynyl-20-deoxyuridine (EdU) is a nucleoside ana-
log of thymidine that is only incorporated into DNA
during active DNA synthesis by proliferating cells. After
incorporation, a fluorescent molecule that reacts specif-
ically with EdU was added, which made the proliferating
cells fluorescent. The Cell-Light EdU DNA cell prolifera-
tion kit (Ribo Bio., Guangzhou, China) was used to deter-
mine the proliferation rate of the A549 cells according to
the manufacturer’s instructions. Briefly, the cells were in-
cubated with 50 μM EdU for 2 h before fixation,
permeabilization, and EdU staining. The cell nuclei were
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stained with Hoechst 33342 at a concentration of 5 μg/mL
for 30 min, and the cells were examined using a flores-
cence microscope (Olympus, Tokyo, Japan).
Clonogenic assay
The cells (2 × 105) were seeded into six-well plates and
subjected to transfection the next day. The plates were
irradiated with doses of 0, 2, 4, 6 or 8 Gy X-ray irradi-
ation given in a single fraction 48 h after transfection.
After incubation at 37 °C and 5 % CO2 for 10–14 days, the
cells were subsequently fixed with methanol and stained
using 1 % crystal violet in 70 % ethanol. The colonies con-
taining 50 or more cells were counted according to our
previous study [22]. SF (surviving fraction) =Number of
colonies/(cells inoculated × plating efficiency). The survival
curve was derived from a multi-target single-hit model:
SF = 1-1-exp(-D/D0)
n [23]. D0 was defined as the dose that
gave an average of one hit per target. The radiation sensi-
tivity enhancement ratio (SER) was measured according to
the multi-target single-hit model.
Flow cytometric analysis of cell apoptosis and cell cycle
An annexin V/7-aminoactinomycin D (7-AAD) apop-
tosis kit (BD Biosciences, San Jose, CA, USA) was
employed to evaluate cellular apoptosis. The cells were
harvested 48 h after being transfected with the RNA and
then stained with Annexin V/7-AAD for 30 min. The re-
sults were analyzed using a FACSCalibur system with
ModFit’s LT software (Becton Dickinson, CA, USA). For
the cell cycle analyses, 24 h after being transfected with
the RNA, the cells were collected and fixed with 70 %
precooled ethanol overnight. After staining with propi-
dium iodide (10 μg/ml; Sigma-Aldrich) in the dark for
30 min, flow cytometry was performed on the FACSCali-
bur system, and the cell cycle distribution was analyzed
using the ModFit LT software.
Western blotting
The proteins in lysates from the cells or exosomes were
resolved using sodium dodecyl sulfate (SDS)–polyacryl-
amide gel electrophoresis and transferred to a nitrocellu-
lose membrane, which was then blocked with phosphate-
buffered saline/Tween-20 containing 5 % non-fat milk.
The membrane was incubated with antibodies to p21,
AKT, p-AKT mTOR and p-mTOR (All from epitomics,
Burlingame, CA, USA). The apoptotic related antibodies
to PARP1, Bcl2 and Bax were all purchased from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). α-Tubulin
(Beyotime, Nantong, China) served as the loading control.
The protein-bound antibodies were detected using an en-
hanced chemiluminescence (ECL) Stable Peroxide solu-
tion (PointBio, Shanghai, China). All protein bands were
visualized by a FluroChem MI imaging system (Alpha
Innotech, Santa Clara, CA, USA) at room temperature.
Purification and characterization of exosomes
Exosomes were prepared from the supernatants of the
sera by differential centrifugation as described below.
Briefly, the sera were centrifuged at 500 × g for 10 min
to remove the cells and then at 16 500 × g for 20 min,
followed by filtration through a 0.22 μm filter to re-
move cell debris. The exosomes were pelleted by ultra-
centrifugation (Beckman Coulter, Inc., CA, USA) at
120 000 × g for 70 min according to a previous report
[21]. For qRT-PCR, Western blot assay and confocal
microscopy, the pellets of the ultracentrifugation pro-
cedure were divided into three equivalent parts and ex-
amined according to the methods described above or
below. Western blotting with the surface marker CD63
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) was
used to confirm that the extract of the pellet contained
extracted exosomes [24]. The protein content of the
exosomes was measured using a BCA™ Protein Assay
Kit (Beyotime, Nantong, China). 40 ug of the quanti-
fied protein samples were loaded into each well of the
gel in this study.
Exosome uptake by confocal microscopy
Exosomes isolated according to the isolation protocol
were washed using an ultra-filtration membrane (10 kDa,
Merck Millipore, Darmstadt, Germany) to remove any
free nucleotides. 1,1′-dioctadecyl-3,3,3′,3′-tetramethylin-
docarbocyanine perchlorate (Dil) was used to label the
membrane component of the exosomes according to
Thery et al. [25]. The exosomes were incubated with
10 μg/mL DiI (Beyotime, Nantong, China) for 15 min at
37 °C and then washed twice with cold phosphate buffered
saline (PBS). The DiI-labeled exosomes were added to
A549 cells grown on chamber slides of a 35 mm dish with
sterile small circular glass and incubated at 37 °C. At the
time points of 0, 30 or 90 min, the cells were harvested
and washed twice with PBS. Then, the cells were
counter-stained with 4’-6-diamidino-2-phenylindole
(DAPI, Invitrogen, Carlsbad, CA, USA) to visualize the
nuclei and were examined using an UltraView VoX con-
focal fluorescence microscope (PerkinElmer, Waltham,
MA, USA).
Statistical analysis
The data are expressed as the means ± standard error
of the mean (SEM) of at least three independent ex-
periments. The standard error bars are shown for all
data points. A Student’s t-test was performed to de-
termine the statistical significance of differences. IBM
SPSS Statistical 19.0 software (IBM, NY, USA) was
utilized for the statistical analyses. P < 0.05 was con-
sidered significant.
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Results
Altered serum miRNA expression profiles of lung cancer
patients after radiotherapy
Using miRNA microarray analysis, we evaluated the
paired serum miRNA expression profiles of three lung
cancer patients before and after radiotherapy. To identify
the differentially expressed miRNAs on the chip, GenEx
analysis was used to generate a list of differentially
expressed miRNAs at FDR = 0 (0 % false discovery rate)
(Additional file 1: Table S1). The significantly altered
miRNAs are listed in Table 1. We identified only one
miRNA (miR-208a) that was up-regulated after radio-
therapy in sera of the lung cancer patients compared
with the same patients’ serum before radiotherapy. Nine
miRNAs were significantly down-regulated (P < 0.05):
miR-29b-3p, miR-200a-3p, miR-126-3p, miR-26b-5p,
miR-200a-3p, miR-15b-3p, let7c/7i-3p and miR-382-5p.
We further validated four representative differentially
expressed miRNAs (miR-208a, miR-126-3p, miR-29b-3p
and miR-200a-3p) as listed in Table 1 by qRT-PCR ana-
lysis. The ratio of the PCR results (AR versus BR) was
compared with miRNA microarray signal intensities to
test the consistency of the two methods. Additional file 2:
Figure S1 displays a comparison of qRT-PCR and micro-
array results for the four differentially expressed miRNAs.
The qRT-PCR analysis confirmed all results obtained by
microarray analysis consistently.
Validation of altered miR-208a expression upon
radiotherapy in both lung cancer patient sera and human
lung cancer cells
Because miR-208a was the only up-regulated miRNA,
we then validated its expression in 30 paired serum sam-
ples by comparing the AR samples with the correspond-
ing BR samples. The clinical characteristics of these
patients were classified and listed in Additional file 3:
Table S2. As shown in Fig. 1a, miR-208a was signifi-
cantly over-expressed in the AR groups compared with
their corresponding BR groups with a P value of 0.039.
Thus, for miR-208a, the qRT-PCR analysis confirmed
the result obtained by microarray analysis, and the dif-
ference was even stronger (>2.178-fold) when validated
in the 30 paired lung cancer serum samples than that
was anticipated from the microarray studies.
We further determined the relative expression of miR-
208a in the NSCLC cell lines (A549, H1299, H1975 and
H460) and non-cancerous bronchial epithelial cell lines
(BEAS-2B and HBE). The qRT-PCR results showed that
miR-208a was expressed in both NSCLC cell lines and
non-cancerous bronchial epithelial cell lines, with clearly
more pronounced expression in the H1975 cells (Fig. 1b).
Moreover, we found that the expression of miR-208a in
A549 and H1299 cells could be further induced by X-ray
irradiation (Fig. 1c and d). In contrast, miR-208a could
not be induced by X-ray irradiation in the non-
cancerous bronchial epithelial HBE cells (Fig. 1e). Fi-
nally, to validate the antagonistic effect in NSCLC cells,
the miR-208a mimics and miR-208a inhibitor were
transfected into A549 and H1299 cells. As shown in
Additional file 4: Figure S2A and S2B, the mimics en-
hanced the miR-208a expression in the two cell lines,
and the inhibitor caused a significant decrease of miR-
208a expression (P < 0.05).
miR-208a directly targeted p21 and affected AKT/mTOR
pathway
To explore the mechanism by which miR-208a executes
its function in lung cancer, we first analyzed its pre-
dicted target genes using three bioinformatic algorithms
(TargetScan, PicTar and miRBase). Among the predicted
candidates, p21 (CDKN1A) was selected for further
analysis. This led us to examine whether ectopic
Table 1 Significant fold changes in serum miRNAs in lung cancer patients before and after radiotherapy analyzed by miRNA
microarray




After RT Before RT After RT Before RT After RT/Before RT p value After RT/Before RT
hsa-miR-29b-3p 4.929 3.756 0.033 0.074 0.444 0.002 −2.254 Down
hsa-miR-223-3p −4.307 −4.850 19.799 28.833 0.687 0.004 −1.456 Down
hsa-miR-126-3p −1.855 −2.132 3.618 4.382 0.826 0.008 −1.211 Down
hsa-miR-26b-Sp –0.080 –0.436 1.057 1.353 0.781 0.025 –1.280 Down
hsa-miR-208a 13.010 14.133 0.000 0.000 2.179 0.030 2.179 Up
hsa-miR-200a-3p 9.266 7.497 0.002 0.006 0.293 0.038 –3.408 Down
hsa-miR-15b-Sp 1.646 0.935 0.319 0.523 0.611 0.039 −1.637 Down
hsa-Iet-7c 3.984 3.518 0.063 0.087 0.724 0.041 −1.382 Down
hsa-miR-382-Sp 7.302 6.578 0.006 0.010 0.605 0.042 −1.652 Down
hsa-Iet-7i-3p 8.801 8.142 0.002 0.004 0.634 0.049 −1.579 Down
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expression of miR-208a could reduce endogenous p21
protein levels in human lung cancer cell lines. Western
blot assays showed that the level of p21 protein was re-
duced significantly by miR-208a over-expression, whereas
miR-208a down-regulation promoted p21 expression
while compared with control treatment (Fig. 2a). These
results indicated p21 as a target of miR-208a for its regula-
tory function in lung cancer.
Because the binding sites of miR-208a were predicted
at positions 86-92 in the 3′-UTR of p21 mRNA (Fig. 2b).
We further test the hypothesis that p21 be a target of
miR-208a using luciferase assays. Reporter by putting
the wild type fragments covering position 1-1500 from
the 3’-UTR region of p21 to the downstream of the lu-
ciferase coding region (named pGL3-UTR-WT, Fig. 2b)
was constructed. miR-208a mimics or inhibitor were
each cotransfected with the above reporters into human
lung cancer A549 cells. Luciferase assay showed that
miR-208a mimics repressed the activity of pGL3-UTR-
WT remarkably, whereas transfection inhibitor en-
hanced the promoter activities (Fig. 2c). In contrast,
transfection of pGL3-UTR-MUT, in which the putative
binding site of miR-208a was mutated, showed no inter-
ference with activity after transfection with either miR-
208a mimics or inhibitor (Fig. 2c). The above results in-
dicated that 3’UTR of p21 harbours a miR-208a binding
site.
Western blot analysis confirmed that transfection with
the miR-208a inhibitor decreased the levels of p-AKT
and p-mTOR expression when compared with the con-
trol group. Conversely, promoting miR-208a expression
increased the activity of the AKT/mTOR pathway,
though it’s not significantly as the effect of the inhibitor
(Fig. 2d). These results indicated that the AKT/mTOR
signaling pathway is involved in the miR-208a-induced
proliferation of human lung cancer cells.
miR-208a increased human lung cancer cell growth in
vitro
The MTT assay, EdU staining and colony formation
were performed to investigate the effect of miR-208a on
the proliferation of A549 cells. As shown in Figs. 3a and
b, over-expression of miR-208a increased the prolifera-
tion rate, and the cells transiently transfected with the
miR-208a mimics exhibited higher clonogenic survival
rates than cells transfected with miRNA-NC, whereas
down-regulation of miR-208a caused the opposite effect
(Fig. 3c, P < 0.05). This effect was verified by a similar
Fig. 1 miR-208a in pairs of serum samples from 30 lung cancer patients before and after radiotherapy and in lung cancer cells was examined
by qRT-PCR. a The average serum miR-208a expression in 30 paired serum samples from lung cancer patients before and after radiotherapy.
b qRT-PCR analysis of the expression of miR-208a in human lung cancer cell lines (A549, H1299, H1975 and H460) and non-cancerous bronchial
epithelial cell lines (BEAS-2B and HBE). The relative expression levels of miR-208a in (c) A549, (d) H1299 and (e) HBE cells after exposure to 0, 2, 4
or 8 Gy X-ray irradiation. The relative serum miR-208a expression level normalized to miR-16 and cellular miR-208a expression normalized to U6
were calculated using the equation described in the Materials and Methods. *P < 0.05 and **P < 0.01 compared with the negative control
Tang et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:7 Page 6 of 14
result in the H1299 cells, which are also an NSCLC cell
line (Additional file 5: Figure S3A and S3B). Taken
together, these results showed that increased miR-208a
expression promoted cell growth and colony formation.
miR-208a decreased cellular apoptosis and disturbed the
cell cycle
Annexin V/7-AAD double-staining assays were con-
ducted to analyze cellular apoptosis. The percentage of
apoptotic cells decreased significantly in the A549 cells
after transfection with the miR-208a mimics compared
with those transfected with miRNA-NC. Specifically, the
apoptosis rates were 5.28 ± 0.68 % and 3.27 ± 0.01 %, re-
spectively (Fig. 4a). In contrast, the apoptosis rates in
the miR-208a-overexpressing H1975 cells increased sig-
nificantly after transfection with the miR-208a inhibitor
(from 9.57 ± 0.47 % to 12.11 ± 0.76 %; Fig. 4b). We add-
itionally addressed the apoptotic molecular component
including PARP1, Bcl2 and Bax in lung cancer cells. Re-
sults showed that miR-208a mimics down-regulated the
expression of apoptotic protein PARP1 and Bax and up-
regulated the anti-apoptotic protein Bcl-2 in A549 cells
(Fig. 4c). In H1975 cells, the apoptotic relative protein
increased expression significantly after transfection with
the miR-208a inhibitor (Fig. 4d), which was consistent
with the results of flow cytometric analysis. However,
while we further examined cell apoptosis rate after
combine treated with radiotherapy, down-regulation of
miR-208a enhanced apoptosis rate after receiving 4 Gy
of X-ray irradiation. But transfection of miR-208a
mimics did not show significant difference in our study
(Additional file 6: Figure S4).
Moreover, cell cycle analysis by flow cytometry demon-
strated that the percentage of cells in the S phase was sig-
nificantly increased and the population of cells in the G0/
G1 phase was decreased after transfection with the miR-
208a mimics in A549 cells. Inhibition of miR-208a in the
miR-208a-overexpressing H1975 cells produced the oppos-
ite effect (Fig. 4e and f). Taken together, these results re-
vealed that miR-208a increased the proliferation of human
lung cancer cells and decreased cellular apoptosis by modu-
lating the cell cycle distribution in human lung cancer cells.
miR-208a increased the radioresistance of A549 cells
To investigate the effect of miR-208a on the radiosensitiv-
ity of human lung cancer cells, clonogenic assays were
performed. Small RNAs targeting miR-208a were trans-
fected into A549 cells followed by irradiation with a range
of X-ray doses. As shown in Fig. 5a, cells transfected with
miR-208a mimics before exposure to 8 Gy X-ray irradiation
Fig. 2 miR-208a affected the levels of the p21/AKT/mTOR pathway in A549 cells. A549 cells were transfected with the miR-208a mimics, negative
control miRNA (miRNA-NC), miR-208a inhibitor or inhibitor-NC for 24 h before lysis. a Western blot analysis the expression levels of p21. b Putative
miR-208a binding sequences in the 3′-UTR of p21 mRNA. c Full-length 3′-UTR of p21 and the mutant sequences were cloned into the downstream of
the luciferase reporter gene named as pGL3-UTR-WT and pGL3-UTR-MUT, respectively. Each of the plasmids and pRL-TK, were cotransfected into A549
cells, either with miR-208a mimics or inhibitor as indicated. Luciferase activity was assayed 48 h after transfection. All experiments were repeated three
times independently. The results are presented as the means ± SEM (n = 3). *P < 0.05. d The membranes were incubated with antibodies to AKT, p-AKT,
mTOR, or p-mTOR. The samples were derived from the same experiment and analyzed under the same experimental conditions
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exhibited higher clonogenic survival rates than those
treated with radiation alone. The miR-208a mimics en-
hanced the radioresistance of the A549 cells (SER = 0.92,
Fig. 5b and c). When the miR-208a inhibitor was trans-
fected into the A549 cells, the cells exhibited smaller
clonogenic survival rates after exposure to 8 Gy X-ray
rradiation and became more sensitive to irradiation
(SER = 1.17, Fig. 5d, e and f ). These results suggested
that miR-208a enhanced the radioresistance of the
A549 lung cancer cells.
Fig. 3 Over-expression of miR-208a promoted cellular proliferation. a The effect of miR-208a on viability of the A549 cells was analyzed using
the MTT assay, and the miRNA-NC-transfected cells were normalized as 100 %. b The proliferating A549 cells were labeled with EdU. The click-it
reaction revealed the EdU staining (red). The cell nuclei were stained with Hoechst 33342 (blue). The images are representative of the results
obtained. c Colony formation assays of A549 cells transfected with miR-208a mimics or miR-208a inhibitor. One thousand cells were seeded onto
each plate. After 10 days, the cells were stained with crystal violet. The colonies consisting of more than 50 cells were counted. The data are
presented as the means ± SEM (n = 4). *P < 0.05 and **P < 0.01 compared with the negative control
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Serum exosome miR-208a was translocated into human
lung cancer cells in an exosome-mediated manner
Because our study found that miR-208a was present in
the serum of lung cancer patients, and exosomes have
recently been recognized as important mediators of
intercellular communication [21], we further investigated
whether serum miR-208a can be transduced into lung
cancer cells by exosomes in vitro. First, Western blot
analysis with antibodies against the exosome-specific
surface marker CD63 was used to confirm that the serial
ultra-centrifugation of the sera resulted in purified exo-
somes. As shown in Fig. 6a, the CD63 expression was
Fig. 4 miR-208a increased the cell apoptosis and disturbed the cell cycle of lung cancer cells. a A549 and (b) H1975 cells were transfected with
the indicated vectors. Two days after transfection, the percentage of apoptotic cells was evaluated using flow cytometry. Western blot analyzed
the apoptotic molecular component including PARP1, Bcl2 and Bax in (c) A549 and (d) H1975 cells. The cell cycle distributions of (e) A549 and
(f) H1975 cells were measured using flow cytometry. *P < 0.05 and **P < 0.01 compared with the negative control
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increased in the AR group compared with the correspond-
ing BR group, suggesting that exosomes can also be in-
duced by radiotherapy in the serum. Then, the qRT-PCR
results showed that miRNAs including miR-208a as well as
the ubiquitous miR-16 were present in the purified exo-
somes (Fig. 6b). To illustrate the major source of miR-208a
after radiotherapy, we detected miR-208a expression in
the culture medium of A549 cells after 0 or 4Gy X-ray ir-
radiation by qRT-PCR analysis. Results showed that radio-
therapy can induce miR-208a secretion from A549 cells to
the culture medium (Fig. 6c). We concluded that the
source of radiation induced miR-208a was secreted from
lung cancer cells.
Next, exosomes containing miRNAs were labeled with
the membrane dye DiI. The labeled exosomes were
added to the culture medium of the A549 cells. After
co-culture for 0, 30 or 90 min with unlabeled recipient
cells, the labeled exosomes as well as A549 cells were
observed using a confocal microscope. The results
showed that the exosomes containing miR-208a could
be incorporated into A549 cells in a time-dependent
manner. Our study demonstrated that serum exosomes
containing miRNAs can be taken up in turn by lung
cancer cells (Fig. 6d) and may subsequently mediate cel-
lular functions.
Discussion
Radiation exposure increases the levels of intracellular
free radical species, followed by DNA strand breaks and
subsequent dysfunction of the mitochondria, endoplas-
mic reticulum and other organelles [26, 27]. These radi-
ation-induced cellular events lead to activation of pro-
apoptotic signaling and eventually to tumor cell killing
[28]. Several studies on the mechanisms of radioresistance
in NSCLC have suggested the potential involvement of ei-
ther p53 mutations, altered expression of survival proteins
including X-linked inhibitor of apoptosis protein (XIAP)
and survivin, or activation of phosphoinositide 3-kinase
(PI3K)/AKT signaling [29]. Identification of molecular
factors responsible for conferring radioresistance and de-
veloping new strategies that increase sensitivity to radi-
ation is warranted.
Accumulating evidence has implicated miRNAs in the
radiosensitivity of various types of cancer cells. Transient
over-expression of miR-181a confers resistance of cer-
vical cancer cells to radiation therapy by targeting the
pro-apoptotic PRKCD gene [23]. High levels of serum
miR-155 and miR-221 are associated with the develop-
ment of severe radiation-induced esophageal toxicity
during an early stage of radiation therapy for non-small
cell lung cancer [30]. However, high-throughput analysis
Fig. 5 miR-208a enhanced the radioresistance of A549 cells. a Colony formation assays and (b) clonogenic cell survival curves were generated.
c D0, Dq and calculated SER values of miRNA-NC- and miR-208a mimic-transfected groups are shown; (d) Colony formation assays and (e) clonogenic
cell survival curves were generated. f D0, Dq and calculated SER values of inhibitor-NC- and miR-208a inhibitor-transfected groups are shown. The SER
was calculated according to the multi-target single hit model
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Fig. 6 Identification and characterization of serum exosome miR-208a translocation into A549 cells. Exosomes were isolated using centrifugation,
filtration and ultracentrifugation as described in the Materials and Methods. a Confirmation of the exosome marker CD63 by Western blot. b qRT-PCR
analysis of miR-208a and miR-16 contained in the exosomes. c qRT-PCR analysis of miR-208a in culture medium of A549 cells. The conditional medium
incubated with A549 cells collected 24 h after exposure to 0 or 4 Gy X-ray irradiation. d Microscopic analysis of the translocation of the pre-labeled
exosomes. The DiI-labeled exosomes displayed red color. The cell nuclei were stained with DAPI (blue). The scale bar indicates 20 μm. *P < 0.05
compared with BR or the group treated with 0 Gy. BR: before radiotherapy; AR: after receiving 60 Gy radiotherapy
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of the serum miRNA expression profile associated with
the radiosensitivity of human lung cancer cells has not
been reported. Our study demonstrated that radiother-
apy produces multiple alterations in the miRNA expres-
sion profile in the serum of lung cancer patients and
that miR-208a was notably increased in the serum after
exposure to a total of 60 Gy X-ray irradiation. Interest-
ingly, our study showed that the expression of miR-208a
could be induced by X-ray irradiation in lung cancer
A549 and H1299 cells but not in the non-cancerous
bronchial epithelial HBE cells, suggesting that lung can-
cer cells were likely to be the major source of increased
miR-208a after radiotherapy. We also found that irradi-
ation increased miR-208a in the culture medium of
A549 cells, which further supported this hypothesis.
Subsequently, we focused our study on the biological
function of the serum miR-208a and found that in-
creased miR-208a played a role in a negative-feedback
mechanism that promoted the proliferation and radiore-
sistance of lung cancer cells.
Studies have shown that miR-208 induces the epithe-
lial to mesenchymal transition of pancreatic cancer cells
and thereby promotes cell metastasis and invasion [31].
Alternatively, another recent report suggested that
miR-208 is a potential onco-miRNA and participates in
the carcinogenesis of esophageal squamous cells by
suppressing SOX6 expression [32]. miR-208a, one of
the mature products of miR-208, which is enriched in
the heart, plays a crucial role in heart health and dis-
ease. Previous studies have identified miR-208a as a po-
tential therapeutic target for systemic metabolic
disorders that affect the heart [33, 34]. This miRNA
was reported to increase endoglin expression to induce
myocardial fibrosis with acute myocardial infarction
(AMI) [35]. Our study expands the list of diverse func-
tions of miR-208a in driving lung cancer proliferation
and radiation response. However, whether miR-208a
could serve as a potential diagnostic and therapeutic
target in cancer merits needs further multi-central clin-
ical studies.
p21, a p53-inducible protein, is a critical regulator of
cell survival and cell cycle by inhibiting both the DNA
synthesis regulator proliferating cell nuclear antigen and
activation of cyclinD1-CDK4/6 complexes [36, 37]. Fur-
thermore, elevated p21 protein levels have been ob-
served in human colon cancer as well as linked to
radioresistance [38]. PI3K/AKT/mTOR pathway activa-
tion plays important roles in NSCLC via both apoptosis
and autophagy inhibition pathway [39]. mTOR is com-
monly activated in NSCLC and is considered to be a po-
tential target for the treatment of NSCLC patients [40].
p21-activated kinase can directly phosphorylate Akt at
Ser473, suggesting that p21 may be a relevant PDK2 re-
sponsible for AKT phosphorylation [41]. In our study,
we identified p21 is directly targeted by miR-208a, and
correspondingly activated AKT and modulated its down-
stream effector mTOR in A549 cells, which was consist-
ent with the results of Chen, et al. [42]. These results
suggested that the p21/AKT/mTOR pathway was in-
volved in the ability of miR-208a to increase the prolifer-
ation of human lung cancer cells. Our report also
showed that up-regulation of miR-208a decreased the
percentage of cells undergoing apoptosis and promoted
G1 phase arrest, while inhibition of miR-208a in H1975
cells, which over-expressed this miRNA, results in the
opposite effects. These results are consistent with the
theory that disturbing the balance between proliferation
and cell death by disruption of the program that regu-
lates cell cycle entry and death can result in cellular car-
cinogenesis [43].
Exosomes have been reported to be minimally invasive,
novel and sensitive biomarkers for prospective tracking and
early detection of tumor recurrence [44, 45]. Exosomes can
mediate communication between hepatocytes and mono-
cytes/macrophages [24]. Hepatocyte-derived miR-122 can
reprogram monocytes and induce sensitization to lipopoly-
saccharide [24]. Exosomal miRNAs are promising for
therapeutic applications, not only for cancer therapy but
also for regenerative medicine [46]. Our results showed
that the exosomes isolated from the sera of lung cancer
patients before or after radiotherapy contained miRNA-
208a and were taken up by the recipient lung cancer
cells. Thus, our study provides proof-of-concept that
exosomes can participate in a novel and intricate
process by which lung cancer cells communicate and may
serve as a proliferation-stimulating and radioresistance-
inducing signal by which the cells may interact with each
other. However, there is still much to be learned regard-
ing the processes by which exosomes are involved in
cellular signal transduction. One recent report showed
that miRNA sorting to exosomes was modulated by cell
activation-dependent changes in the miRNA target
levels in the producer cells [47]. If exosomes interact
with a recipient cell through specific receptor–ligand
interactions, whether this venue of communication
could be expected to be cell type-specific and the mech-
anisms whereby miRNAs are sorted to exosomes de-
mand further research.
Conclusion
In conclusion, we evaluated the alterations in the
serum miRNA profiles of lung cancer patients after
radiotherapy. Among the differentially expressed miR-
NAs, miR-208a promoted lung cancer cell proliferation
and decreased cell apoptosis by targeting p21 and
AKT/mTOR pathway. Our demonstration that miR-
208a is present in exosomes supported the hypothesis
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that exosomes may be a vehicle by which to modulate
recipient cell functions. Our findings suggest that miR-
208a served as a novel tumor accelerator miRNA and
may be a potential therapeutic target for the treatment
of human lung cancer.
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crystal violet. The colonies consisting of more than 50 cells were counted.
The data are presented as the means ± SEM (n = 4). *P < 0.05 and **P < 0.01
compared with the negative control. (JPG 1411 kb)
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